Halozyme Therapeutics (HALO) Set to Announce Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of $0.73 per share for the quarter. Halozyme Therapeutics has set its FY24 guidance at $3.55-3.90 EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.07. The company had revenue of $195.88 million during the quarter, compared to the consensus estimate of $201.72 million. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. On average, analysts expect Halozyme Therapeutics to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Halozyme Therapeutics Trading Up 0.1 %

Shares of Halozyme Therapeutics stock traded up $0.06 during trading on Tuesday, hitting $55.53. The stock had a trading volume of 96,474 shares, compared to its average volume of 1,242,172. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36. The stock has a market cap of $7.07 billion, a PE ratio of 22.92, a PEG ratio of 0.57 and a beta of 1.27. Halozyme Therapeutics has a 12 month low of $32.83 and a 12 month high of $57.08. The firm’s fifty day simple moving average is $50.25 and its 200-day simple moving average is $42.79.

Insider Activity

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the completion of the transaction, the chief financial officer now directly owns 15,480 shares of the company’s stock, valued at $803,876.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 45,000 shares of company stock valued at $2,294,050 in the last quarter. 2.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HALO. Piper Sandler lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $48.00 to $51.00 in a research note on Friday, June 7th. JMP Securities dropped their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 8th. Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Benchmark upped their price target on Halozyme Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. Finally, The Goldman Sachs Group increased their price objective on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $58.38.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.